Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Income from Continuing Operations of 129013000.0 for Q1 2026, up 5.05% year-over-year from 122814858.51 in Q1 2025, and up 1.84% quarter-over-quarter from 131427000.0 in Q4 2025.
Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Income from Continuing Operations for 10 consecutive years, with 129013000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 5.05% year-over-year to 129013000.0; the TTM figure through Mar 2026 stood at 562549000.0 (down 20.88% YoY), while the FY2025 annual figure was 512540000.0, down 21.23% from the prior year.
- Income from Continuing Operations climbed to 129013000.0 in Q1 2026 per DNLI's latest filing, from 131427000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 183383000.0 in Q2 2023 and bottomed at 172227000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 94744000.0 across 5 years, with a median of 110077000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 411.91% — and 2024, when it sank 155.56%.
- Denali Therapeutics' Income from Continuing Operations stood at 98678000.0 in 2022, then dropped by 21.07% to 119473000.0 in 2023, then climbed by 1.59% to 117570000.0 in 2024, then fell by 11.79% to 131427000.0 in 2025, then grew by 1.84% to 129013000.0 in 2026.
- Business Quant data shows DNLI's Income from Continuing Operations at 129013000.0 in Q1 2026, 131427000.0 in Q4 2025, and 129882000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -130.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -130.55 Mn |
| Mar 31, 2026 | -129.01 Mn |
| Dec 31, 2025 | -131.43 Mn |
| Sep 30, 2025 | -129.88 Mn |
| Jun 30, 2025 | -172.23 Mn |
| Mar 31, 2025 | -135.87 Mn |
| Dec 31, 2024 | -117.57 Mn |
| Sep 30, 2024 | -110.08 Mn |
| Jun 30, 2024 | -101.88 Mn |
| Mar 31, 2024 | -104.60 Mn |
| Dec 31, 2023 | -119.47 Mn |
| Sep 30, 2023 | -99.35 Mn |
| Jun 30, 2023 | 183.38 Mn |
| Mar 31, 2023 | -112.78 Mn |
| Dec 31, 2022 | -98.68 Mn |
| Sep 30, 2022 | -103.30 Mn |
| Jun 30, 2022 | -58.79 Mn |
| Mar 31, 2022 | -69.12 Mn |
| Dec 31, 2021 | -75.26 Mn |
| Sep 30, 2021 | -84.59 Mn |